{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:07:37Z","timestamp":1790212057812,"version":"4.1.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017559","name":"Recordati Rare Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017559","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Osilodrostat is an 11\u03b2-hydroxylase inhibitor that has demonstrated high efficacy in Cushing\u2019s syndrome (CS) in clinical trials; however, real-world data remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate dosing patterns, effectiveness, and safety of osilodrostat in patients with adrenocorticotropic hormone (ACTH)\u2013dependent CS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This retrospective analysis included 26 adults with ACTH-dependent CS (15 with Cushing\u2019s disease [CD] and 11 with ectopic CS [ECS]) treated with osilodrostat between 2020 and 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Osilodrostat was introduced as first-line therapy in 12 of 26 patients. A titration regimen was used in 21 patients, and a block-and-replace approach in five. A therapeutic effect was achieved in 92% at a median dose of 5 mg\/day (4.5 mg\/day in CD and 6.5 mg\/day in ECS) within 14 days. Morning cortisol normalized in 92% of cases, and urinary free cortisol in 75%. The median clinical score decreased from 9 to 4, and muscle strength increased from 50% to 75% of normal. All 22 patients requiring potassium supplementation showed improvement, with a median time to dose reduction of 10 days. Systolic\/diastolic blood pressure decreased from 142\/87 to 124\/70 mmHg, enabling reduction of antihypertensive therapy in 22 of 23 patients. Among 20 patients with diabetes, 18 reduced the number or dose of antidiabetic medications, including insulin. Adverse events were mild to moderate and included fatigue and nausea (34.6% each), adrenal insufficiency (30.8%), and dizziness (23.1%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In real-world clinical practice, osilodrostat provided rapid and effective biochemical control and clinical improvement in ACTH-dependent CS, with a manageable safety profile and effective doses in the low-to-moderate range.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1866631","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:24:18Z","timestamp":1783657458000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Individualized osilodrostat treatment for patients with ACTH-dependent Cushing\u2019s syndrome: real-world evidence"],"prefix":"10.3389","volume":"17","author":[{"given":"Aleksandra","family":"Gilis-Januszewska","sequence":"first","affiliation":[{"name":"Chair and Department of Endocrinology, Jagiellonian University Medical College","place":["Krakow, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Gamrat-\u017bmuda","sequence":"additional","affiliation":[{"name":"Chair and Department of Endocrinology, Jagiellonian University Medical College","place":["Krakow, Poland"]},{"name":"Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College","place":["Krakow, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Minasyan","sequence":"additional","affiliation":[{"name":"Chair and Department of Endocrinology, Jagiellonian University Medical College","place":["Krakow, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyna","family":"Wi\u0119c\u0142awek","sequence":"additional","affiliation":[{"name":"Chair and Department of Endocrinology, Jagiellonian University Medical College","place":["Krakow, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Hubalewska-Dydejczyk","sequence":"additional","affiliation":[{"name":"Chair and Department of Endocrinology, Jagiellonian University Medical College","place":["Krakow, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01961-X","article-title":"Cushing's syndrome","volume":"402","author":"Gadelha","year":"2023","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00588-w","article-title":"Cushing syndrome","volume":"11","author":"Nieman","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1785054","article-title":"Cushing syndrome of different etiologies - cardiometabolic complications, venous thromboembolic events and mortality: data from ERCUSYN Krakow database","volume":"17","author":"Minasyan","year":"2026","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13114","article-title":"Clinical presentation and etiology of Cushing's syndrome: data from ERCUSYN","volume":"34","author":"Valassi","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0556","article-title":"Management of endocrine disease: mortality remains increased in Cushing's disease despite biochemical remission: a systematic review and meta-analysis","volume":"172","author":"van Haalen","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13175","article-title":"Cardiovascular complications of Cushing's syndrome: impact on morbidity and mortality","volume":"34","author":"Clayton","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0464","article-title":"High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry","volume":"181","author":"Valassi","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0569","article-title":"Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up","volume":"169","author":"Ntali","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-024-01485-x","article-title":"Medical management pathways for Cushing's disease in pituitary tumors centers of excellence (PTCOEs)","volume":"28","author":"Giustina","year":"2025","journal-title":"Pituitary"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.732240","article-title":"Effectiveness of medical treatment of Cushing's disease: a systematic review and meta-analysis","volume":"12","author":"Sim\u00f5es Corr\u00eaa Galendi","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.12","article-title":"Management of cushing disease","volume":"7","author":"Tritos","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2023.12.003","article-title":"A clinical perspective on ectopic Cushing's syndrome","volume":"35","author":"Ragnarsson","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17101611","article-title":"Ectopic Cushing's syndrome in advanced small-cell lung cancer (SCLC): clinical challenges and therapeutic insights","volume":"17","author":"Gamrat-\u017bmuda","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0242679","article-title":"Ectopic ACTH syndrome of different origin-Diagnostic approach and clinical outcome. Experience of one Clinical Centre","volume":"15","author":"Pale\u0144-Tytko","year":"2020","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0877","article-title":"Management of endocrine disease: Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion","volume":"182","author":"Young","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac691","article-title":"Efficacy and safety of osilodrostat in paraneoplastic Cushing syndrome: a real-world multicenter study in France","volume":"108","author":"Dormoy","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1060884","article-title":"Individualized medical treatment options in Cushing disease","volume":"13","author":"Gilis-Januszewska","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ecl.2018.01.001","article-title":"Morbidity of Cushing syndrome and impact of treatment","volume":"47","author":"Webb","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac178","article-title":"Randomized trial of osilodrostat for the treatment of Cushing disease","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ24-0153","article-title":"Osilodrostat treatment in patients with Cushing's disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4)","volume":"71","author":"Shimatsu","year":"2024","journal-title":"Endocr J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0317","article-title":"Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension","volume":"187","author":"Fleseriu","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-022-01280-6","article-title":"Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2)","volume":"25","author":"Fleseriu","year":"2022","journal-title":"Pituitary"},{"key":"B24","article-title":"Osilodrostat (Isturisa) for Cushing's disease","volume":"63","year":"2021","journal-title":"Med Lett Drugs Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2025.010","article-title":"Osilodrostat for Cushing syndrome","volume":"48","year":"2025","journal-title":"Aust Prescr"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1897106","article-title":"Osilodrostat for the treatment of Cushing's disease","volume":"22","author":"Rasool","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S315359","article-title":"Clinical utility of osilodrostat in Cushing's disease: review of currently available literature","volume":"17","author":"Perosevic","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf027","article-title":"Osilodrostat treatment for adrenal and ectopic Cushing syndrome: integration of clinical studies with case presentations","volume":"9","author":"Fleseriu","year":"2025","journal-title":"J Endocr Soc"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2023.0041","article-title":"COVID-19 infection in a patient with Cushing's disease on osilodrostat treatment","volume":"74","author":"Bogus\u0142awska","year":"2023","journal-title":"Endokrynol Pol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.16768","article-title":"Complete remission of hypercortisolemia in a patient with severe ectopic Cushing syndrome caused by small-cell lung cancer","volume":"134","author":"Gamrat","year":"2024","journal-title":"Pol Arch Intern Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.ijem_260_23","article-title":"Efficacy and safety of osilodrostat in managing Cushing's syndrome: a systematic review and meta-analysis","volume":"28","author":"Nagendra","year":"2024","journal-title":"Indian J Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf046","article-title":"Osilodrostat treatment of Cushing syndrome in real-world clinical practice: findings from the ILLUSTRATE study","volume":"9","author":"Fleseriu","year":"2025","journal-title":"J Endocr Soc"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1236465","article-title":"Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension","volume":"14","author":"Gadelha","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf207","article-title":"Osilodrostat dose impact on efficacy\/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4","volume":"193","author":"Fleseriu","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11102-022-01268-2","article-title":"Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples","volume":"25","author":"Fleseriu","year":"2022","journal-title":"Pituitary"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-22-0311","article-title":"Osilodrostat in Cushing's disease: the management of its efficacy and the pitfalls of post-surgical results","volume":"2022","author":"Antonini","year":"2022","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2021.06.012","article-title":"Osilodrostat: a review of recent clinical studies and practical recommendations for its use in the treatment of Cushing disease","volume":"27","author":"Yuen","year":"2021","journal-title":"Endocr Pract"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ24-0696","article-title":"Safety management in Cushing syndrome during osilodrostat treatment based on morning blood cortisol level","volume":"72","author":"Katabami","year":"2025","journal-title":"Endocr J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf103","article-title":"Management of osilodrostat therapy in patients with Cushing's syndrome: a modified Delphi consensus panel","volume":"9","author":"Samson","year":"2025","journal-title":"J Endocr Soc"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae201","article-title":"Improved clinical outcomes during long-term osilodrostat treatment of Cushing disease with normalization of late-night salivary cortisol and urinary free cortisol","volume":"9","author":"Newell-Price","year":"2024","journal-title":"J Endocr Soc"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14217575","article-title":"Real-world data on the efficacy and safety of osilodrostat in patients with Cushing's disease in Spain","volume":"14","author":"Araujo-Castro","year":"2025","journal-title":"J Clin Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14551","article-title":"Osilodrostat in Cushing's disease: the risk of delayed adrenal insufficiency should be carefully monitored","volume":"98","author":"Castinetti","year":"2023","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf633","article-title":"Real-world osilodrostat effectiveness and safety in nonpituitary Cushing syndrome","volume":"111","author":"Tabarin","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14103518","article-title":"Osilodrostat safety profile: findings from real-world data in the FAERS database","volume":"14","author":"Popa Ilie","year":"2025","journal-title":"J Clin Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-026-10020-1","article-title":"Use of osilodrostat in a block-and-replace and titration strategy for Cushing's syndrome: a position paper by French experts","volume":"27","author":"Castinetti","year":"2026","journal-title":"Rev Endocr Metab Disord"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf185","article-title":"A preliminary model to tailor osilodrostat in patients with ACTH-dependent Cushing's syndrome","volume":"193","author":"Piazzola","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf206","article-title":"Chronotherapy with once-daily osilodrostat improves cortisol rhythm, quality of life, and sleep in Cushing's syndrome","volume":"110","author":"Ferrari","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1660316","article-title":"Liver impairment and medical management of Cushing syndrome and MACS","volume":"16","author":"Minasyan","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0329088","article-title":"Safety assessment of osilodrostat: the adverse event analysis based on FAERS database by means of disproportionality analysis","volume":"20","author":"Li","year":"2025","journal-title":"PloS One"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-024-01471-3","article-title":"Osilodrostat improves blood pressure and glycemic control in patients with Cushing's disease: a pooled analysis of LINC 3 and LINC 4 studies","volume":"28","author":"Fleseriu","year":"2025","journal-title":"Pituitary"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.09.005","article-title":"Osilodrostat treatment for Cushing syndrome: 5 years on since regulatory approval","author":"Yuen","year":"2025","journal-title":"Endocr Pract"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02359-6","article-title":"Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease","volume":"47","author":"Pivonello","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ25-0089","article-title":"Blood steroid hormone profile and clinical outcomes following switching from metyrapone to osilodrostat in patients with Cushing disease","volume":"72","author":"Yokozeki","year":"2025","journal-title":"Endocr J"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03229-0","article-title":"Matching-adjusted indirect comparison of osilodrostat versus metyrapone for the treatment of Cushing's syndrome","volume":"42","author":"Hickey","year":"2025","journal-title":"Adv Ther"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1866631\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:24:19Z","timestamp":1783657459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1866631\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":54,"alternative-id":["10.3389\/fendo.2026.1866631"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1866631","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"1866631"}}